Piramal Enterprises to list Rs. 103.97 crore debentures

The meeting of Administrative Committee of the Board of Directors of Piramal Enterprises Limited has approved allotment of 1,000 Secured, Rated, Listed, Redeemable Principal Protected, Market Linked Non-Convertible Debentures each having a face value of Rs. 10,00,000, at a further issue price of Rs. 10,39,670 per Debenture, aggregating to Rs. 103.967 crore on private placement basis.

These Debentures are proposed to be listed on the Debt Segment and Capital Market Segment of National Stock Exchange of India Limited (NSE) and BSE Limited respectively, with NSE being the designated Stock Exchange.

Shilpa Medicare’s Unit IV, Jadcherla, Telangana facility has received Health Canada GMP Approval

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022.

The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.

This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities.